<DOC>
	<DOCNO>NCT02576301</DOCNO>
	<brief_summary>Phase 1 investigate maximum tolerate dose OXi4503 single agent combination intermediate-dose cytarabine subject relapsed/refractory AML MDS . Phase 2 investigate overall response rate OXi4503 combination intermediate-dose cytarabine 1 ) subject MDS failure 1 prior hypomethylating agent ( Arm A ) 2 ) subject relapse refractory AML treatment failure 1 prior chemotherapy regimen ( Arm B ) .</brief_summary>
	<brief_title>Dose Escalation OXi4503 Single Agent Combination With Cytarabine w/Subsequent Ph 2 Cohorts AML MDS</brief_title>
	<detailed_description>Phase 1 dose escalation component ass safety , PK/PD , preliminary efficacy OXi4503 single agent subject relapsed/refractory AML MDS , safety PK/PD combination OXi4503 intermediate-dose cytarabine subject AML/MDS . Phase 2 ass preliminary efficacy OXi4503+cytarabine combination 2 cohort .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<criteria>1 . Provide informed consent 2 . ≥ 18 year age 3 . Phase 1 ( dose escalation ) subject must either : AML fail achieve complete remission morphologic complete remission MDS Marrow blast must &gt; 5 % disease fail least 1 prior hypomethylating agent 4 . Phase 2 ( expansion ) subject must either MDS relapsed/refractory AML 5 . Eastern Cooperative Oncology Group performance status 0 , 1 , 2 6 . Total bilirubin ≤ 2 7 . Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level ≤ 2.5 time upper limit normal ( ULN ) 8 . Serum creatinine &lt; 2.5 time ULN 9 . Prothrombin time ( PT ) /international normalize ratio ( PTT ) normal range ± 25 % 10 . Women childbearing potential 11 . Males female partner childbearing potential must agree use physicianapproved contraceptive method 1 . Acute promyelocytic leukemia 2 . Absolute peripheral blood myeloblast count great 20,000/mm3 3 . Uncontrolled hypertension 4 . History congenital long QT syndrome torsades de pointes 5 . Pathologic bradycardia heart block 6 . Prolonged baseline QTc 7 . Hiistory ventricular arrhythmia 8 . Myocardial infarction and/or new ST elevation 9 . Any history hemorrhagic stroke 10 . Symptomatic congestive heart failure 11 . Major hemorrhagic event within 28 day 12 . Suggestive central nervous system involvement leukemia 13 . Any open wound 14 . Pregnant nursing subject exclude 15 . Treatment anticancer therapy 16 . Treatment colchicine exclude . 17 . Psychiatric disorder would interfere consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
</DOC>